医学
败血症
新生儿败血症
重症监护医学
免疫活性
不利影响
抗生素
儿科
免疫学
药理学
免疫系统
生物
微生物学
标识
DOI:10.1097/00005237-199603000-00008
摘要
Neonatal sepsis continues to be a major source of morbidity and mortality among preterm infants. Although traditional antibiotic therapy continues to be the mainstay of treatment for sepsis, intravenous gammaglobulin (IVIG) is being used in both prevention and treatment of neonatal sepsis as a means to boost the infant's immunocompetence. The article explores the conflicting results of clinical trials testing the efficacy of IVIG for neonatal sepsis. IVIG is discussed with regard to its mechanism of action, pharmacokinetics, dosage and administration, adverse reactions, and nursing implications.
科研通智能强力驱动
Strongly Powered by AbleSci AI